← Search & browse all drugs

cyclobenzaprine

M03BX08

Forms & Strengths

Oral tablet: 5 mg
Oral tablet: 7.5 mg
Oral tablet: 10 mg
Extended-release capsule (ER): 15 mg
Extended-release capsule (ER): 30 mg

Adult Dosing

Immediate-release: 5 mg to 10 mg orally three times daily as needed; maximum 10 mg per dose and 30 mg per day; limit use to 2 to 3 weeks.
Extended-release (Amrix): 15 mg to 30 mg orally once daily.

Pediatric Dosing

Children < 15 years: Safety and efficacy have not been established.
Adolescents >= 15 years: Dosing similar to adult immediate-release (5 mg to 10 mg orally three times daily) if indicated for short-term use.

Indications

Adjunct to rest and physical therapy for the relief of muscle spasm associated with acute, painful musculoskeletal conditions.

Mechanism of Action

Centrally acting skeletal muscle relaxant structurally related to tricyclic antidepressants.
Acts primarily at the brain stem to reduce tonic somatic motor activity, influencing both alpha and gamma motor neurons.

Contraindications

Hypersensitivity to cyclobenzaprine or any component of the formulation.
Concurrent use of monoamine oxidase (MAO) inhibitors or within 14 days of discontinuing them.
Acute recovery phase of myocardial infarction, and patients with arrhythmias, heart block, or conduction disturbances.
Congestive heart failure.
Hyperthyroidism.

Adverse Reactions

Drowsiness
Dizziness
Dry mouth
Fatigue
Headache
Nausea
Constipation
Blurred vision
Tachycardia

Drug Interactions

MAO inhibitors: Risk of severe, potentially fatal hyperpyretic crisis, seizures, and death.
CNS depressants (alcohol, opioids, sedatives, hypnotics, anxiolytics): Enhanced central nervous system depression and psychomotor impairment.
Serotonergic agents (SSRIs, SNRIs, tricyclic antidepressants): Risk of serotonin syndrome.
Tramadol: Increased risk of seizures and serotonin syndrome.

Curated Content: Needs Vetting Before Put to Clinical Use